0 0 0
Dieser Online-Shop verwendet Cookies für ein optimales Einkaufserlebnis. Dabei werden beispielsweise die Session-Informationen oder die Spracheinstellung auf Ihrem Rechner gespeichert. Ohne Cookies ist der Funktionsumfang des Online-Shops eingeschränkt. Sind Sie damit nicht einverstanden, klicken Sie bitte hier.

Shear, Dodiuk-Gad Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions

Current and Future Trends

ISBN: 978-981-13-1488-9

Auflage: 1st Ed.

Erscheinungsdatum: Oktober 2018

Einband: Hardcover

Seitenzahl: 314 p.

Illustrationen: 95 ill.

Verlag: Springer

Lieferzeit ab Ihrer Bestellung: 2-14 Tage je nach Lieferbarkeit und Verlag

Beschreibung

  • Clear clinical scenarios help guide the reader to understand the science and treatment of cutaneous drug reactions
  • Special chapters on the pharmacology, immunology and genetics of cutaneous drug eruptions bring readers up-to-date knowledge and insights
  • Full colour clinical plates and schemata make drug reactions understandable and helpful to practitioners and patients
  • International regulatory innovations can lead the way to safer development and deployment of important treatments

This resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development.
The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes. Patients and practitioners often face important decisions about therapy after a drug eruption, including treatment, cross-reactivity with future pharmaceuticals, genetic considerations and dealing with long-term sequelae after a reaction. An international team of experts and leaders in the field share their story and insights into the scientific details and relevant clinical context.